Currently, the company’s portfolio includes PAT-1251, a phase 2-ready LOXL2 inhibitor for the treatment of idiopathic pulmonary, liver and kidney fibrosis ... in rodent models of nonalcoholic ...

While new drug molecules are typically tested in vivo in two preclinical species to better understand how they are transported and eliminated by the kidney ... in rodent and non-rodent models ...